Skip to main content
SpringerLink
Log in

Management of hepatocellular cancer

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

The nearly ubiquitous association of hepatocellular cancer (HCC) with underlying liver dysfunction portends a dismal prognosis. At the time of presentation with HCC, many patients have advanced cirrhosis that precludes effective therapy. Important prognostic factors include characteristics of the tumor (size, location, involvement of major blood vessels) and the functional state of the liver (quantified by synthetic function and portal hypertension). Localized tumors in a noncirrhotic liver may be treated successfully with surgical resection. In the setting of mild to moderate cirrhosis, localized therapy such as radiofrequency ablation, percutaneous ethanol ablation, chemoembolization, or Yttrium 90 microsphere infusion may be options, depending on the liver reserve and resources available. In the setting of advanced cirrhosis, treatment of the tumor may exacerbate liver decompensation, resulting in a shortened survival. In all of these instances, regardless of the therapy pursued, the underlying field defect with malignant potential remains in place. Liver transplantation has been employed to resolve both life-threatening problems, but it is fraught with many barriers. Appropriate patient selection and the use of adjuvant therapies are being pursued to improve the outcome of transplantation for HCC. Patients may have limited therapy options if they have poor performance status, are not surgical candidates, have a tumor that extends into the main portal vein, or have metastases to distant lymph nodes or organs. Chemotherapy is of marginal efficacy. Emerging therapies exploiting molecular targets are being explored with some promise.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Chang MH, Chen CJ, Lai MS, et al.: Universal hepatitis B vaccination in Taiwan and the incidence of hepato-cellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997, 336:1855–1859.

    Article  PubMed  CAS  Google Scholar 

  2. Halm U, Etzrodt G, Schiefke I, et al.: A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. Ann Oncol 2000, 11:113–114.

    Article  PubMed  CAS  Google Scholar 

  3. Valle JW, Dangoor A, Beech J, et al.: Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study. Br J Cancer 2005, 92:628–630.

    Article  PubMed  CAS  Google Scholar 

  4. Hong RL, Tseng YL: A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2003, 51:433–438.

    PubMed  CAS  Google Scholar 

  5. Yang TS, Wang CH, Hsieh RK, et al: Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2000, 89:750–756.

    Article  PubMed  CAS  Google Scholar 

  6. Guan Z, Want Y, Maoleekoonpairoj S, et al.: Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepato-cellular carcinoma. Br J Cancer 2003, 89:1865–1869.

    Article  PubMed  CAS  Google Scholar 

  7. Fuchs CS, Clark JW, Ryan DP, et al.: A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2002, 94:3186–3191.

    Article  PubMed  CAS  Google Scholar 

  8. Stuart K, Tessitore J, Rudy J, et al.: A Phase II trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma. Cancer 1999, 86:410–414.

    Article  PubMed  CAS  Google Scholar 

  9. Mok TS, Leung RW, Lee SD, et al.: A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepato-cellular carcinoma. Cancer Chemother Pharmacol 1999, 44:307–311.

    Article  PubMed  CAS  Google Scholar 

  10. Leung TW, Patt YZ, Lau WY, et al.: Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999, 5:1676–1681.

    PubMed  CAS  Google Scholar 

  11. Yeo W, Zee B, Leung WT, et al.: A phase HI study of doxorubicin (A) versus cisplatin (P)/ interferona-2b (I)/ doxorubicin (A)/ fluorouracil (F) combination chemotherapy (PIAF) for inoperable hepatocellular carcinoma (HCC). / Clin Oncol 2004, Proc ASCO 2004, 22:4026.

    Google Scholar 

  12. Lee J, Park JO, Kim WS, et al.: Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol 2004, 54:385–390.

    Article  PubMed  CAS  Google Scholar 

  13. Patt YZ, Hassan MM, Lozano RD, et al.: Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepato-cellular carcinoma. J Clin Oncol 2003, 21:421–427.

    Article  PubMed  CAS  Google Scholar 

  14. Boucher E, Corbinais S, Brissot P, et al.: Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin cisplatinum and infusional 5-fluorouracil (ECF regimen). Cancer Chemother Pharmacol 2002, 50:305–308.

    Article  PubMed  CAS  Google Scholar 

  15. Yang TS, Wang CH, Hsieh RK, et al: Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I–II trial. Ann Oncol 2002, 13:1771–1778.

    Article  PubMed  CAS  Google Scholar 

  16. Taieb J, Bonyhay L, Golli L, et al: Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer 2003, 98:2664–2670.

    Article  PubMed  CAS  Google Scholar 

  17. Schwartz JD, Lehrer D, Mandeli, et al: Thalidomide in hepatocellular cancer (HCC) with optional interferon-a upon progression. ProcASCO 2003, 22:301.

    Google Scholar 

  18. Patt Y, Hassan M, Lozano R, et al: Phase II Trail of Thalomid (Thalidomide) for treatment of non-nesectable nepatocellular narcinoma (HCC). Paper presented at the American Society of Clinical Oncology Annual Meeting. New Orleans, LA; May 20–23, 2000.

  19. Kong HL, Boyer MJ, Lim R, et al: Phase II trial of thalidomide in unresectable hepatocellular carcinoma (HCC)?a cancer therapeutics research group (CTRG) study. Paper presented at the American Society of Clinical Oncology Annual Meeting. San Francisco, CA; May 12–15, 2001.

  20. Lin AY, Brophy N, Fisher GA, et al: Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer 2005, 103:119–125.

    Article  PubMed  CAS  Google Scholar 

  21. Reubi JC, Waser B, Schaer JC, et al: Regulatory peptide receptors in human hepatocellular carcinomas. Gut 1999, 45:766–774.

    Article  PubMed  CAS  Google Scholar 

  22. Reubi JC, Zimmerman A, Jonas S, et al: Somatostatin receptor sstl-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001, 28:836–846.

    Article  PubMed  CAS  Google Scholar 

  23. Kouroumalis E, Skordilis P, Thermos K, et al: Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998, 42:442–447.

    Article  PubMed  CAS  Google Scholar 

  24. Yuen MF, Poon RT, Lai CL, et al: A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002, 36:687–691.

    Article  PubMed  CAS  Google Scholar 

  25. Barbare JC, Bouche O, Bonnetain F, et al: Treatment of advanced hepatocellular carcinoma with longacting octreotide: preliminary results of a randomized placebo-controlled trial (FFCD-ANGH 2001-01 CHOC). / Clin Oncoloy 2005, 23:16S.

    Google Scholar 

  26. Simonetti RG, Liberati A, Angiolini C, et al: Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 1997, 8:117–136.

    Article  PubMed  CAS  Google Scholar 

  27. Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme). Lancet 1998, 352:17-20.

  28. Perrone F, Gallo C, Daniele B, et al: Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trial. Curr Pharm Des 2002, 8:1013–1019.

    Article  PubMed  CAS  Google Scholar 

  29. Chow PK, Tai BC, Tan CK, et al: High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology 2002, 36:1221–1226.

    Article  PubMed  CAS  Google Scholar 

  30. Dawson LA, Normolle D, Baiter JM, et al: Analysis of radiation-induced liver disease using the Lyman NTCP model. IntJ Radiat Oncol Biol Phys 2002, 53:810–821.

    Article  Google Scholar 

  31. McGinn CJ, Haken RK, Ensminger WD, et al: Treatment of intrahepatic cancers with radiation doses based on a normal tissue complication probability model. / Clin Oncol 1998, 16:2246–2252.

    CAS  Google Scholar 

  32. Lawrence TS, Tepper JE, Blackstock JW: Fluoropyrimidineradiation interactions in cells and tumors. Semin Radiat Oncol 1997, 7:260–266.

    Article  PubMed  Google Scholar 

  33. Matsuzaki Y, Osuga T, Chiba T, et al: New effective treatment using proton irradiation for unresectable hepatocellular carcinoma. Intern Med 1995, 34:302–304.

    PubMed  CAS  Google Scholar 

  34. Ohara K, Okumura T, Tsuji H, et al: Clearance of parenchymal tumors following radiotherapy: analysis of hepatocellular carcinomas treated by proton beams. Radiother Oncol 1996, 41:233–236.

    Article  PubMed  CAS  Google Scholar 

  35. Geschwind JF, Salem R, Carr BI, et al: Yttrium-90 micro-spheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004, 127(5 Suppl l):S194-S205.

    Article  PubMed  CAS  Google Scholar 

  36. Arii S, Yamaoka Y, Futagawa S, et al.: Results of surgical and nonsurgical treatment for small-sized hepato-cellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatobgy 2000, 32:1224–1229.

    Article  CAS  Google Scholar 

  37. Livraghi T, Goldberg SN, Lazzaroni S, et al.: Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology 2000, 214:761–768.

    PubMed  CAS  Google Scholar 

  38. Santambrogio R, Opocher E, Costa M, et al: Survival and intra-hepatic recurrences after laparoscopic radio-frequency of hepatocellular carcinoma in patients with liver cirrhosis [discussion 225–226]. J Surg Oncol 2005, 89:218–225.

    Article  PubMed  Google Scholar 

  39. Gazelle GS, Goldberg SN, Solbiati L, et al.: Tumor ablation with radio-frequency energy. Radiology 2000, 217:633–646.

    PubMed  CAS  Google Scholar 

  40. Ahmed M, Goldberg SN: Thermal ablation therapy for hepatocellular carcinoma. J Vasc Interv Radiol 2002, 13:S231-S244.

    Article  PubMed  Google Scholar 

  41. Tateishi R, Shiina S, Teratani T, et al.: Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 2005, 103:1201–1209.

    Article  PubMed  Google Scholar 

  42. Lencioni RA, Allgaier HP, Cioni D, et al: Small hepato-cellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003, 228:235–240. A randomized study comparing local nonsurgical therapy for small primary liver tumors.

    Article  PubMed  Google Scholar 

  43. Vivarelli M, Guglielmi A, Ruzzenente A, et al: Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg 2004, 240:102–107.

    Article  PubMed  Google Scholar 

  44. Sigurdson ER, Ridge JA, Kemeny N, et al: Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol 1987, 5:1836–1840.

    PubMed  CAS  Google Scholar 

  45. Ramsey DE, Kernagis LY, Soulen MC, et al: Chemo-embolization of hepatocellular carcinoma. J Vasc Interv Radiol 2002, 13:S211-S221.

    Article  PubMed  Google Scholar 

  46. Stuart K: Chemoembolization in the management of liver tumors. Oncologist 2003, 8:425–437.

    Article  PubMed  Google Scholar 

  47. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med 1995, 332:1256-1261.

  48. Llovet JM, Real MI, Montana X, et al.: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002, 359:1734–1739. A randomized study demonstrating survival benefit of chemoembolization.

    Article  PubMed  Google Scholar 

  49. Yamakado K, Nakatsuka A, Ohmori S, et al: Radiofrequency ablation combined with chemoembolization in hepatocellular carcinoma: treatment response based on tumor size and morphology. J Vasc Interv Radiol 2002, 13:1225–1232.

    Article  PubMed  Google Scholar 

  50. The Liver Cancer Study Group of Japan: Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer 1994, 74:2772–2780.

    Article  Google Scholar 

  51. Bismuth H, Majno PE: Hepatobiliary surgery. J Hepatol 2000, 32(1 Suppl):208–224.

    Article  PubMed  CAS  Google Scholar 

  52. Llovet JM, Fuster J, Bruix J: Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatobgy 1999, 30:1434–1440.

    Article  CAS  Google Scholar 

  53. Llovet JM, Bruix J, Gores GJ: Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. Hepatobgy 2000, 31:1019–1021.

    Article  CAS  Google Scholar 

  54. Iwatsuki S, Gordon RD, Shaw BW Jr, et al: Role of liver transplantation in cancer therapy. Ann Surg 1985, 202:401–407.

    Article  PubMed  CAS  Google Scholar 

  55. Ringe B, Pichlmayr R, Wittekind C, et al: Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 1991, 15:270–285.

    Article  PubMed  CAS  Google Scholar 

  56. Bismuth H, Chiche L, Adam R, et al: Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993, 218:145–151.

    Article  PubMed  CAS  Google Scholar 

  57. Mazzaferro V, Regalia E, Dod R, et al: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693–699. Landmark paper demonstrating the benefit of transplantation for the treatment of primary liver cancer.

    Article  PubMed  CAS  Google Scholar 

  58. Yao FY, Ferrell L, Bass NM, et al: Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatobgy 2001, 33:1394–1403.

    Article  CAS  Google Scholar 

  59. Wiesner R, Edwards E, Freeman R, et al: Model for endstage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003, 124:91–96.

    Article  PubMed  Google Scholar 

  60. Kubo S, Nishiguchi S, Hirohashi K, et al: Effects of longterm postoperative interferonalpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized controlled trial. Ann Intern Med 2001, 134:963–967.

    PubMed  CAS  Google Scholar 

  61. Shiratori Y, Shiina S, Teratani T, et al: Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003, 138:299–306.

    PubMed  Google Scholar 

  62. Philip PA, Mahoney M, Thomas J, et al: Phase II Trial of erlotinib (OSI-774) in patients with hepatocellular or biliary cancer. J Clin Oncol 2004, Proc ASCO 2004, 22:14S.

    Google Scholar 

  63. Schwartz JD, Schwartz M, Goldman J, et al: Bevacizumab in hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein. Paper presented at the American Society of Clinical Oncology 2005 Gastrointestinal Cancers Symposium. Hollywood, FL; January 27–29, 2005.

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Robert H. Lurie Comprehensive Cancer Center, 676 North Saint Clair, Suite 850, 60611, Chicago, IL, USA

    Mary F. Mulcahy MD

Authors
  1. Mary F. Mulcahy MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mulcahy, M.F. Management of hepatocellular cancer. Curr. Treat. Options in Oncol. 6, 423–435 (2005). https://doi.org/10.1007/s11864-005-0045-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-005-0045-7

Keywords

Search

Navigation